Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Gemcitabine (Primary) ; Capecitabine; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms TIGeR-PaC
- Sponsors RenovoRx
- 27 Aug 2024 According to a RenovoRx media release, the second interim analysis for this study will be triggered by the 52nd event, which is estimated to occur in late 2024 or early 2025.
- 27 Aug 2024 According to a RenovoRx media release, Mr. Bagai will discuss recent corporate achievements including progress on RenovoRx's pivotal ongoing Phase III TIGeR-PaC clinical trial at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City.
- 14 Aug 2024 According to RenovoRx media release, the first patient has been enrolled at the University of Nebraska Medical Center (UNMC). UNMC will help drive enrollment of the TIGeR-PaC trial to completion next year because they treat a larger number of patients diagnosed with pancreatic cancer.